Analysts Expect Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.28 Per Share

Equities analysts expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report ($1.31) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.48) and the highest is ($1.10). Five Prime Therapeutics posted earnings of ($1.04) per share during the same quarter last year, which would indicate a negative year over year growth rate of 26%. The firm is expected to issue its next earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full-year earnings of ($4.32) per share for the current year, with EPS estimates ranging from ($4.47) to ($4.12). For the next year, analysts anticipate that the business will post earnings of ($5.26) per share, with EPS estimates ranging from ($6.58) to ($4.27). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.22). The firm had revenue of $5.77 million during the quarter, compared to analyst estimates of $7.45 million. Five Prime Therapeutics had a negative return on equity of 41.52% and a negative net margin of 221.67%.

A number of analysts have recently issued reports on the company. BidaskClub raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 21st. Wedbush lifted their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the stock a “hold” rating in a research note on Friday, August 10th. ValuEngine raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 26th. Leerink Swann assumed coverage on Five Prime Therapeutics in a research note on Thursday, September 13th. They issued an “outperform” rating and a $24.00 price target on the stock. Finally, Citigroup lowered their price target on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 20th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Five Prime Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $29.67.

Shares of NASDAQ:FPRX opened at $12.19 on Wednesday. The company has a market capitalization of $457.51 million, a PE ratio of -2.27 and a beta of 3.34. Five Prime Therapeutics has a 1 year low of $10.35 and a 1 year high of $24.82.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its stake in Five Prime Therapeutics by 61.1% during the second quarter. Citadel Advisors LLC now owns 147,047 shares of the biotechnology company’s stock worth $2,325,000 after buying an additional 55,783 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Five Prime Therapeutics by 14.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 175,895 shares of the biotechnology company’s stock worth $2,781,000 after buying an additional 22,572 shares during the last quarter. Aquilo Capital Management LLC acquired a new position in Five Prime Therapeutics during the second quarter worth $1,025,000. ARK Investment Management LLC boosted its stake in Five Prime Therapeutics by 165.9% during the second quarter. ARK Investment Management LLC now owns 183,094 shares of the biotechnology company’s stock worth $2,895,000 after buying an additional 114,240 shares during the last quarter. Finally, Algert Global LLC acquired a new position in Five Prime Therapeutics during the second quarter worth $476,000. 85.99% of the stock is currently owned by institutional investors.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Recommended Story: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply